Table 3. Rh antigen reactivity and... | American Society of Hematology

Table 3.

Rh antigen reactivity and corresponding molecular backgrounds

	Rh phenotype with routine reagents	Rh antibodies in serum	Anti-e MoAbs						Anti–low and –high-frequency antigens					Molecular background
	Rh phenotype with routine reagents	Rh antibodies in serum	MS16	MS21	MS63	MS62	MS69	MS70	RH10/20	RH32	RH50	RH19	RH46	RHD	RHCE
Controls
ceMO	Dccee; weak e	0	w	w	0	0	0	0	0	0	0	0	+	D	ceMO/ceMO
RN	DCCee; weak C, weak e	0	w	0	0	0	w	0	0	+	0	+	0	D	RN/RN
C48	Dccee	0	+	+	+	+	w	+	0	0	0	+	+	D	ce(48)/ce(48)
Group A
1	Dccee weak D	anti-RH18, anti-E	+	+	w	+	+	+	+	0	0	0	+	DAR	ceAR/ceEK
2	Dccee weak D	anti-RH18, anti-D	+	+	w	0/w	+	+	+	0	0	0	+	DAR	ceAR/ceEK
3	Dccee weak D	anti-RH18, anti-D	+	+	+	+	+	+	0	0	0	0	+	DAR	ceEK/ceEK
4	Dccee weak D	anti-RH18, anti-D	+	+	0	0	w	+	+	0	0	0	+	DAR	ceAR/ceAR
5	Dccee weak D	anti-RH18, anti-C	+	+	0	0	w	+	+	0	0	0	+	DAR	ceAR/ceAR
6	Dccee	anti-RH18, anti-E	+	+	+	+	+	+	0	0	0	0	+	DAR/D(667)	ceEK/ceBI
Group B
9	ddCcee	anti-RH34, anti-D	+	+	+	+	+	0	+	0	0	+	+	D-Ce(3-8)-D	ce^s(1006)/ce^s (1006)
10	ddCcee	anti-RH34	+	+	+	+	+	0	+	0	0	+	+	D-Ce(3-8)-D	ce^s(1006)/ce^s (1006)
Group C
11	DCcee weak C, weak e	anti-e, anti-Ce	+	w	0	0	w	0	0	+	0	+	+	D	R^N/ceMO
12	DccEe weak e	anti-e, anti-Ce	0	0	+	+	0	0	w	0	0	w	+	D/D(674)	cE/ce^s(340)
Group D
13	Dccee weak e	0	w	w	0	0	0	0	0	0	+	0	+	D/DIVa	ceMO/ce-D(5)-ce
14	DCcee weak C weak e	0	+	+	0	w	0	0	w	+	0	+	+	D	R^N/ce^s(748)
15	DCcee weak C weak c weak e	0	w	0	0	0	w	0	0	w	0	w	0	D	R^N/ce-D(4–9)-ce
16	DCcee weak C weak e	0	+	w	0	0	w	0	0	+	0	+	+	D	R^N/ceMO
17	DccEe weak e	0	0	0	+	+	0	0	w	0	0	w	+	D	cE/ce^s(340)

	Rh phenotype with routine reagents	Rh antibodies in serum	Anti-e MoAbs						Anti–low and –high-frequency antigens					Molecular background
	Rh phenotype with routine reagents	Rh antibodies in serum	MS16	MS21	MS63	MS62	MS69	MS70	RH10/20	RH32	RH50	RH19	RH46	RHD	RHCE
Controls
ceMO	Dccee; weak e	0	w	w	0	0	0	0	0	0	0	0	+	D	ceMO/ceMO
RN	DCCee; weak C, weak e	0	w	0	0	0	w	0	0	+	0	+	0	D	RN/RN
C48	Dccee	0	+	+	+	+	w	+	0	0	0	+	+	D	ce(48)/ce(48)
Group A
1	Dccee weak D	anti-RH18, anti-E	+	+	w	+	+	+	+	0	0	0	+	DAR	ceAR/ceEK
2	Dccee weak D	anti-RH18, anti-D	+	+	w	0/w	+	+	+	0	0	0	+	DAR	ceAR/ceEK
3	Dccee weak D	anti-RH18, anti-D	+	+	+	+	+	+	0	0	0	0	+	DAR	ceEK/ceEK
4	Dccee weak D	anti-RH18, anti-D	+	+	0	0	w	+	+	0	0	0	+	DAR	ceAR/ceAR
5	Dccee weak D	anti-RH18, anti-C	+	+	0	0	w	+	+	0	0	0	+	DAR	ceAR/ceAR
6	Dccee	anti-RH18, anti-E	+	+	+	+	+	+	0	0	0	0	+	DAR/D(667)	ceEK/ceBI
Group B
9	ddCcee	anti-RH34, anti-D	+	+	+	+	+	0	+	0	0	+	+	D-Ce(3-8)-D	ce^s(1006)/ce^s (1006)
10	ddCcee	anti-RH34	+	+	+	+	+	0	+	0	0	+	+	D-Ce(3-8)-D	ce^s(1006)/ce^s (1006)
Group C
11	DCcee weak C, weak e	anti-e, anti-Ce	+	w	0	0	w	0	0	+	0	+	+	D	R^N/ceMO
12	DccEe weak e	anti-e, anti-Ce	0	0	+	+	0	0	w	0	0	w	+	D/D(674)	cE/ce^s(340)
Group D
13	Dccee weak e	0	w	w	0	0	0	0	0	0	+	0	+	D/DIVa	ceMO/ce-D(5)-ce
14	DCcee weak C weak e	0	+	+	0	w	0	0	w	+	0	+	+	D	R^N/ce^s(748)
15	DCcee weak C weak c weak e	0	w	0	0	0	w	0	0	w	0	w	0	D	R^N/ce-D(4–9)-ce
16	DCcee weak C weak e	0	+	w	0	0	w	0	0	+	0	+	+	D	R^N/ceMO
17	DccEe weak e	0	0	0	+	+	0	0	w	0	0	w	+	D	cE/ce^s(340)

Results are represented by “+” for a normal positive reaction, “w” for a weak positive reaction, and “0” for a negative reaction. “0/w” stands for reactions that may vary depending of the batch used. RH49 (STEM) low-frequency antigen expressed on some RH:−18 RBCs was not tested (serum was not available in the laboratory).24 The molecular background indicates the homozygous or heterozygous status of the RHD gene only when it could be determined by family study or by the presence of 2RHD genes at sequencing analysis. For the RHCEalleles, the major mutation is indicated in parentheses, except for group 1, in which mutations are multiple. ce^sstands for other alleles with at least mutation at 733. Patients 7 and 8 (DAR-ceAR/DAR-ceAR) do not appear in this Table, as recent transfusion made Rh typing not meaningful.

F3-150

RH46 antigen expression has been tested with polyclonal and monoclonal reagents.

View Large

This Feature Is Available To Subscribers Only